MedTrace Logo

Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation

NCT02730494 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-02-05

No results posted yet for this study

Summary

The primary objective of this study is to study the vaginal flora colonisation equivalence between the tablet and capsule dosage forms of a treatment with Lcr Regenerans® between D0 (V1) and Dend of treatment.

Conditions

  • Candidiasis, Vulvovaginal

Interventions

DEVICE

Lcr Regenerans® vaginal capsules

DEVICE

Lcr Regenerans® vaginal tablet

Sponsors & Collaborators

  • Biose

    lead INDUSTRY

Principal Investigators

  • Yann Dr LENGLET · Hospital center Jacques LACARIN of VICHY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-01-31
Completion
2018-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730494 on ClinicalTrials.gov